Search results

Haematology

08 June 2026

TALVEY®▼ (talquetamab) is accepted for use within NHS Scotland for treating relapsed and refractory multiple myeloma after three or more lines of treatment

For UK national, medical and pharmaceutical trade media

Haematology

08 June 2026

NICE issues Final Draft Guidance recommending DARZALEX® (daratumumab) with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

For UK regional consumer, medical and pharmaceutical trade media only

Oncology

11 May 2026

RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations

For UK medical and pharmaceutical trade media only

Oncology

08 May 2026

NICE issues Final Draft Guidance recommending that RYBREVANT®▼ (amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults

For UK national, medical and pharmaceutical trade media only

Oncology

18 December 2025

NICE issues Final Draft Guidance recommending RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib) as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations

For UK medical and pharmaceutical trade media only

Oncology

08 December 2025

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

For UK national, medical and pharmaceutical trade, and Scottish regional media only

Haematology

17 November 2025

TALVEY®▼ (talquetamab) receives positive NICE recommendation in Final Draft Guidance for treating relapsed and refractory multiple myeloma after three or more lines of treatment

For UK national, medical and pharmaceutical trade media

Immunology

11 November 2025

SMC accepts TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use within NHS Scotland

For UK medical and pharmaceutical trade media only

Immunology

19 September 2025

Icotrokinra shows superiority to deucravacitinib in the first reported head-to-head trials of investigational targeted oral peptide for the treatment of plaque psoriasis

For UK medical and pharmaceutical trade media only

28 August 2025

NICE issues final guidance recommending TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis in the UK

For UK medical and pharmaceutical trade media only

You are now leaving Johnson & Johnson Innovative Medicine UK

You are now leaving Johnson & Johnson Innovative Medicine UK

You are now leaving Johnson & Johnson Innovative Medicine UK

You are now leaving Johnson & Johnson Innovative Medicine UK

You are now leaving Johnson & Johnson Innovative Medicine UK

You are now leaving Johnson & Johnson Innovative Medicine UK

The Newsroom is intended to provide resources for media professionals only.

The Newsroom is intended to provide resources for media professionals only.

Search Results

No Results

Search results

You are now leaving Johnson & Johnson Innovative Medicine UK